Find News

Filter articles

Applied Filters

Showing 61 to 70 of 730 results

Amgen appeals against PTAB Sanofi decision


Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors.

China, Canada and US labs collaborate over neurological disorder therapies

Canada, China, US10-04-2019

Chinese companies have entered into a research agreement with scientists in the US and Canada to develop a therapy for neurological disorders by using the natural power of the immune system.

Duane Morris hires Winston & Strawn lawyer

Taiwan, US10-04-2019

Duane Morris & Selvam has strengthened its IP practice with the addition of John Alison from Winston & Strawn.

Athena asks for rehearing on invalidated neurological disorder patent


Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.

Abbvie faces multiple Humira antitrust suits


AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

EPO grants eukaryotic cell CRISPR patent to Charpentier


The European Patent Office has issued a new CRISPR/Cas9 patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.

English court claims jurisdiction in Unilever antibody dispute


The English High Court will hear a patent dispute between a subsidiary of biopharmaceutical company Sanofi and British-Dutch consumer goods brand Unilever.

EPO president refers plant patentability decision for appeal


European Patent Office president António Campinos will refer a recent decision on the patentability of exclusively obtained by essentially biological processes to the office’s Enlarged Board of Appeal.

Cancer Research UK forms immunotherapy alliance


Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.

Thermo Fisher expands into gene therapy in $1.7bn deal


Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.

Showing 61 to 70 of 730 results